X4 Pharmaceuticals
One Broadway, 14th Floor
Cambridge
Massachusetts
02142
United States
Website: http://www.x4pharma.com/
124 articles with X4 Pharmaceuticals
-
The company plans to use the cash to advance its two lead drug programs into the clinic.
-
X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway With X4P-001-IO
11/10/2017
The data, primarily generated from biopsies of tumors from melanoma patients, demonstrated important changes in the tumor microenvironment.
-
X4 Pharma Release: First Clinical Data From Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients With Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/3/2017
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T-cell Infiltration in Human Metastatic Melanoma
-
X4 Pharma Release: Clinical Data for X4P-001-IO in Combination With Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma
10/30/2017
The data were presented at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29 in Philadelphia.
-
Updated Clinical Data From Combination of X4P-001-IO and Inlyta (Axitinib) in Patients With Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/26/2017
X4 Pharmaceuticals today announced that the American Association for Cancer Research (AACR) has published Phase 1 data from an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib), Pfizer’s VEGFR kinase inhibitor.
-
X4 Pharma Release: Initial Clinical Trial Data For Combination Of X4P-001-IO And Inlyta (Axitinib) Demonstrate Encouraging Disease Control Rates And Durable Clinical Responses In Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
9/11/2017
-
X4 Pharma Release: First Data From Combination Of X4P-001-IO And Inlyta (Axitinib) In Patients With Clear Cell Renal Cell Carcinoma Will Be Presented At The European Society Of Medical Oncology 2017 Congress
8/31/2017
-
X4 Pharma Announces Rare Disease Research Collaboration With Yale
8/2/2017
-
X4 Pharma Announces Initiation Of The Phase II Expansion Of Its Phase I/II Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma
5/25/2017
-
X4 Pharma Announces Initiation Of A Phase 2/3 Clinical Study Of X4P-001-LD In Patients With WHIM Syndrome, A Rare Genetic Primary Immunodeficiency Disease
1/30/2017
-
X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma
1/26/2017
-
X4 Pharma Release: Company Appoints Dr. Sudha Parasuraman As Chief Medical Officer
1/23/2017
-
X4 Pharma Announces New Data For Lead Candidate X4P-001 In Renal Cell Carcinoma At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
11/30/2016
-
X4 Pharma Appoints Nancy Lurker As Chair Of Board Of Directors
10/5/2016
-
X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma
9/27/2016
-
X4 Pharma To Present At The 23rd Annual Biocentury Newsmakers In The Biotech Industry Conference
9/7/2016
-
X4 Pharma To Present At Canaccord Genuity’s 36th Annual Growth Conference
8/8/2016
-
X4 Pharma Appoints John K. Celebi As Chief Operating Officer
6/13/2016
-
X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma
5/9/2016
-
X4 Pharma Announces Data Presentation For Lead Candidate X4P-001 At AACR Annual Meeting
4/20/2016